1. Home
  2. MIRM vs GEO Comparison

MIRM vs GEO Comparison

Compare MIRM & GEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • GEO
  • Stock Information
  • Founded
  • MIRM 2018
  • GEO 1984
  • Country
  • MIRM United States
  • GEO United States
  • Employees
  • MIRM N/A
  • GEO N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • GEO Homebuilding
  • Sector
  • MIRM Health Care
  • GEO Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • GEO Nasdaq
  • Market Cap
  • MIRM 3.3B
  • GEO 3.7B
  • IPO Year
  • MIRM 2019
  • GEO 1994
  • Fundamental
  • Price
  • MIRM $76.06
  • GEO $20.64
  • Analyst Decision
  • MIRM Strong Buy
  • GEO Strong Buy
  • Analyst Count
  • MIRM 9
  • GEO 5
  • Target Price
  • MIRM $73.89
  • GEO $42.00
  • AVG Volume (30 Days)
  • MIRM 914.8K
  • GEO 3.0M
  • Earning Date
  • MIRM 08-06-2025
  • GEO 08-06-2025
  • Dividend Yield
  • MIRM N/A
  • GEO N/A
  • EPS Growth
  • MIRM N/A
  • GEO 153.61
  • EPS
  • MIRM N/A
  • GEO 0.63
  • Revenue
  • MIRM $429,161,000.00
  • GEO $2,452,358,000.00
  • Revenue This Year
  • MIRM $52.71
  • GEO $7.69
  • Revenue Next Year
  • MIRM $19.71
  • GEO $18.85
  • P/E Ratio
  • MIRM N/A
  • GEO $32.91
  • Revenue Growth
  • MIRM 62.33
  • GEO 1.17
  • 52 Week Low
  • MIRM $36.86
  • GEO $11.75
  • 52 Week High
  • MIRM $76.40
  • GEO $36.46
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 77.75
  • GEO 38.23
  • Support Level
  • MIRM $73.12
  • GEO $20.25
  • Resistance Level
  • MIRM $76.02
  • GEO $21.33
  • Average True Range (ATR)
  • MIRM 2.39
  • GEO 0.70
  • MACD
  • MIRM 0.04
  • GEO 0.12
  • Stochastic Oscillator
  • MIRM 96.66
  • GEO 21.79

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About GEO Geo Group Inc (The) REIT

The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.

Share on Social Networks: